Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

Sermorelin vs Ipamorelin vs Tesamorelin: Receptor Class and Separate Lot Files

A research-use comparison of sermorelin, ipamorelin, and tesamorelin: GHRH versus GHSR classes, attributed findings, and separate lot files—not a ranking.

Sermorelin vs Ipamorelin vs Tesamorelin: Receptor Class and Separate Lot Files

Sermorelin and tesamorelin are GHRH-pathway analogues, whereas ipamorelin acts through the growth-hormone secretagogue receptor (GHSR). The original overview of this page asks readers to keep those receptor classes distinct, to record sequence-stability and exposure differences, and to choose matched endpoints and controls when more than one analogue appears in the same file.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not a ranking, not claims about a Velnacor lot, and not instructions for use in people or animals.

GHRH receptor versus GHSR signaling

Sermorelin is a name for GHRH(1-29). A 1999 review by Prakash and Goa summarized published clinical literature on sermorelin in the diagnosis and treatment of children with idiopathic GH deficiency (Prakash and Goa, 1999). That review is cited here for identity and for the existence of a published clinical-research record. It is not a protocol.

Tesamorelin is reviewed and studied as a GHRH / growth hormone-releasing factor analogue, including as GHRH(1-44) in a pooled clinical analysis (Wang and Tomlinson, 2009; Falutz et al., 2010). Falutz and colleagues reported reductions in visceral adipose tissue and increases in IGF-I, relative to placebo, in randomized studies of people with HIV and abdominal fat accumulation (Falutz et al., 2007; Falutz et al., 2010). Those are findings in the populations and designs of those papers. They do not document sermorelin, and they are not use instructions. A tesamorelin identity note is at What Is Tesamorelin?.

Ipamorelin is a pentapeptide GHSR agonist. Raun and colleagues reported GH release from rat pituitary cells and in rat and swine models, with ACTH and cortisol responses in swine that did not differ significantly from GHRH, unlike GHRP-6 and GHRP-2 in the same design (Raun et al., 1998). That selectivity finding belongs to ipamorelin’s receptor class. See What Is Ipamorelin?. A related comparison that also includes CJC-1295 is at CJC-1295 vs Sermorelin vs Ipamorelin.

Sequence stability, exposure, and labeling

Even within the GHRH family, sermorelin (GHRH 1-29) and tesamorelin (a GHRH analogue, including the GHRH(1-44) identification used in Falutz et al., 2010) are not the same material. Exposure windows and documentation should be written per analogue. Combination SKUs, if offered, are additional rows. Shared shipping does not merge receptor classes or fragment lengths.

Citation flag. A single peer-reviewed study that compared sermorelin, ipamorelin, and tesamorelin head-to-head in one experimental design was not verified for this draft. The comparison is a documentation framework built from identity papers and from findings reported for each analogue in its own literature. It is not a pooled efficacy table.

What to keep distinct in a three-analogue file
Name What the cited literature identifies What not to assume
Sermorelin GHRH(1-29), as reviewed in published clinical literature (Prakash and Goa, 1999). That a 1-29 fragment is the same material as tesamorelin.
Tesamorelin A GHRH / GRF analogue, including the GHRH(1-44) identification used in Falutz et al. (Wang and Tomlinson, 2009; Falutz et al., 2010). That VAT or IGF-I findings in those trials document another analogue.
Ipamorelin A GHSR/GHRP-receptor pentapeptide with reported GH selectivity in the models of Raun et al. (Raun et al., 1998). That GH release in one receptor class predicts the other.

Matched endpoints and separate lot files

When more than one analogue is studied or purchased, endpoints, time-course, and reports should be specified per material. How to Read a Peptide COA, lot traceability, and How to Evaluate a Peptide Supplier: B2B Checklist apply independently to each line item.

Catalog records exist for sermorelin, tesamorelin, and ipamorelin, and for some combination SKUs. There is not a standalone public landing page for every name; use the product directory and the COA Library, then confirm each SKU in the inquiry. For packing at supply scale, see wholesale peptides.

Selected published literature

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007. PubMed 18031173. Review article; cited for identity, not as a use instruction.
  2. Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009;18(3):303-310. doi:10.1517/13543780802707658. PubMed 19243281. Review article; cited for analogue identity.
  3. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. PubMed 18057338. Cited as published clinical-research observations, not as a use instruction.
  4. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490. PubMed 20554713. Cited as published clinical-research observations, not as a use instruction.
  5. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PubMed 9849822.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0